ELVN241220C2500
- 0.00
- 0.000.00%
Enliven Therapeutics Newsroom
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40
Express News | Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40
Enliven Therapeutics Reports Q3 Results and Clinical Progress
Express News | Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32
Enliven Therapeutics: Promising Clinical Developments and Robust Financial Position Justify Buy Rating
Express News | Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026
Enliven Therapeutics | 10-Q: Q3 2024 Earnings Report
Enliven Therapeutics | 8-K: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Express News | Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate
Express News | Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Express News | Enliven Therapeutics Q3 Income From Operations USD -27.068 Million
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $37
Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
Enliven Therapeutics Announces Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia; Reported Cumulative MMR Rate Of 44% (8/18) By 24 Weeks, With Stable Or Deepening Responses Between Weeks 12 And 24, Which Continues To...